32 results about "Cd4 receptors" patented technology

Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by any one of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

Chimeric antibodies for CD4 receptor comprising a variable or antigen binding region of a non-human origin specific for CD4 receptor and a constant region of human origin are disclosed. These antibodies are useful as therapeutic agents for auto-immune disorders.

The invention provides a fusion protein, which comprises an antigen binding portion of an A32 human antibody, or variant thereof, and one of the following: (a) an antigen-binding portion of a second antibody or variant thereof, wherein the second antibody binds to an epitope of an envelope protein of a human immunodeficiency virus (HIV) that is exposed upon the HIV binding to a CD4 receptor, (b) an immunogenic portion of an envelope protein of a HIV, or a variant thereof, or (c) a soluble CD4 (sCD4) polypeptide capable of binding to HIV, or a or variant thereof.

A method is provided for detecting a presence of HIV virus in a sample comprising: taking a culture of recombinant cells which (a) are capable of cell division, (b) express CD4 receptor and one or more additional cell surface receptors necessary to allow the HIV virus to infect, (c) enable the HIV virus to replicate and infect the noninfected cells in the cell culture, and (d) comprise a reporter sequence introduced into the recombinant cells comprising a reporter gene whose expression is regulated by a protein specific to HIV viruses which is expressed from a genome of an HIV virus upon infection of the recombinant cell by the HIV virus; contacting the cell culture with a sample to be analyzed for the presence of HIV virus in the sample; and detecting a change in a level of expression of the reporter gene in cells in the recombinant cell culture. The method can be used to detect the presence of HIV virus in a sample, detect the presence of different strains of HIV virus in a sample, detect HIV drug resistance in a sample, determine what combination of one or more anti-HIV agents would be effective in treating a patient, and screen compositions for anti-HIV activity.

This invention is called: the experiment and method of the protein envelope which is allosteric restructuring of the HIV-Env gene DNA and its antigenic immunity responsive HIV. It relates to the domain of life sciences and medicine sciences. It is confirmed that gp120 of the HIV protein envelope or the gp160 of the antigenic vaccine combines with cell CD4+ that can induce the infirm immunogen of the alloantigen of the immune tolerant receptor CD4 and can not induce the HIV to infect the immune response of the parasitifer. It can also eliminate the multi-clone group of hill of the wild virus which is of fast copy the initial infection virus, high variability and sequence diversity. This invention can develop the non-spark human tolerant immunity HIV vaccine of the protein envelope which is allosteric restructuring of the HIV-Env gene DNA, the HIV preventive vaccine that can provide the scientific basis of the direct animal experiment and direct clinical trial of human being. It also provides the enforceable anti-HIV cell model, rodent model, non-human Primates model and the research program of human clinical trial.

A method for preventing infection of helper T and other target cells by human immunodeficiency virus type 1 ('HIV-1') and for preventing or treating acquired immunodeficiency syndrome ('AIDS') by exposing target cells to a synergistic combination of at least one attachment inhibitor and at least one fusion inhibitor. The attachment inhibitors are compounds that bind to the CD4 receptor on target cells or that bind to gp120 on HIV-1, e.g., antibodies, and the fusion inhibitors compounds that interact with gp4l to inhibit or prevent its interaction with target cells, e.g., pentafuside.

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also "binding sites") on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by any one of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

The invention relates to a horizontal chamber for treating patients suffering from the human immunodeficiency virus HIV. The patients position themselves in a supine decubitus position, and the chamber has a cover in the upper part thereof, at a variable height, comprising a magnetic pulse generator. Furthermore, electrodes are arranged in the area occupied by the patient, said electrodes being fixed in the lower area and variable in the upper area of the patient's body, generating electrical impulses complementing the magnetic impulses.; The control and regulation mechanisms of the chamber ensure a certain dosage of electromagnetic energy acting on the ionic channels of the protein GP120 present in the human immunodeficiency virus HIV, which open up and lose the necessary energy used to interact with the CD4 receptors that are marker molecules in the cellular surface and recognise certain antibodies.

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by anyone of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

The present invention relates to conjugated molecules comprising a peptide derived from the CD4 receptor coupled to an organic molecule via a linker and a method for their preparation. The organic molecules include anionic polypeptides of 5 to 21 amino acids. The conjugated molecule can be used for antiviral therapy, that is, for the treatment of AIDS.

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by any one of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

An electroimmunization chamber consists of a horizontal space designed for treatment of patients with HIV, who place themselves in supine lying position, and the upper part of which has a cover with adjustable height with a magnetic pulse generator. The patient rest area also contains fixed electrodes in the lower part and variable electrodes in the upper patient area, which generate electrical impulses that supplement the magnetic pulses. The mechanisms for control and regulation of the chamber ensure dosing of electro-magnetic energy that acts on the ionic channels of the GP120 protein that is present in HIV. These channels open and lose the necessary energy used for interacting with the CD4 receptors, which are marking molecules on the cell surface, which recognize certain antibodies.

The invention relates to an anti-HIV immune response apparatus of an HIV-Env DNA recombinant envelope protein antigen and a method thereof, belonging to life science and medicinal fields. The clinic experiment in human body prove that vaccines derived from HIV envelope protein gp120 or gp160 can not prevent HIV infection, because the HIV envelope protein gp120 or gp160 is a heterogeneous specific ligand that can specifically bind with CD4<+> cells-specific receptor CD4<+> receptor and induce immunological tolerance mechanism of human body but can not inducing immune response mechanism for effectively eliminating HIV. The invention can be used for searching a method for solving immunological tolerance mechanism of human body, developing an anti-HIV vaccine derived from HIV-Env DNA recombinant envelope protein antigen for preventing and treating HIV that does not induce immunological tolerance mechanism of human body, and providing sufficient scientific reference for direct animal model experiments and direct clinical human trials.

The present invention relates to an infectious particle having a surface displaying a ligand binding to a CD4 receptor for selectively infecting dividing CD4+ cells, said particle comprising: (a) one or more structural proteins, and (b) a vector containing a gene of interest functional in a CD4+ cell, said gene of interest encoding a Forkhead box protein 3 or a protein inducing expression of Forkhead box protein 3 in the CD4+ cell.